Health Economics›Non-small cell lung cancer nonsquamous›Maintenance after first-line therapy

Maintenance after first-line therapy

Non-small cell lung cancer nonsquamous · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pemetrexed and Bevacizumab Variant #01	—	R 43 211	21d	—	23.3 mo	2	R 86 422 PFS proxy	1
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	—	19.6 mo	52	R 992 271 PFS proxy	1
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	4.1 mo	11.2 mo	4	R 52 900 PFS proxy	2

3 of 3 regimens shown